Technology

Alnylam Pharmaceuticals has partnered with Inceptive to apply generative AI to siRNA design, pairing Inceptive's biology-trained models with Alnylam's two decades of proprietary RNAi data to accelerate candidate discovery.

Prescryptive Health’s chief commercial officer discusses the results of a market access survey that asked industry executives about DTC models, affordability, and patient access.

Harpreet Singh, former FDA Oncology Division Director and current chief medical officer at Precision for Medicine notes how evolving FDA review standards, expedited approval programs, and emerging AI tools are reshaping the regulatory landscape for biopharma companies.

In today's Pharmaceutical Executive Daily, Reuters reports that lower-priced oral GLP-1 pills from Eli Lilly and Novo Nordisk are drawing patients away from compounded weight loss medications, Gilead Sciences' renews its five-year collaboration with WHO and Johnson and Johnson’s collaboration with the Department of Health Abu Dhabi, finally Partha Anbil argues that truly industrializing machine learning and AI in life sciences requires systems that are scientifically credible, clinically defensible, regulatorily traceable, and operationally sustained.

Life science organizations that will lead the next decade ar those that deploy systems that are scientifically credible, clinically defensible, regulatorily traceable, and operationally sustained.

New partnerships from Gilead Sciences and Johnson & Johnson highlight how healthcare companies are using collaborations to expand global disease initiatives and accelerate development of AI-enabled healthcare infrastructure.

Eli Lilly acquires Engage Biologics in up to $202 million deal to strengthen its genetic medicines portfolio with a non-viral DNA delivery platform designed to improve durability, tolerability, and re-dosing potential.

Bristol Myers Squibb and Incyte expand AI capabilities through major collaborations aimed at embedding agentic and molecular AI directly into drug discovery, development, and enterprise operations.

Regeneron and Parabilis Medicines partner to discover and develop antibody-Helicon conjugates, aiming to create a new class of therapies capable of targeting historically “undruggable” intracellular proteins.

Trialynx’s CEO discusses the benefits of using AI for trial design and how to find the AI companies doing the most promising work.

How existing technologies and approaches such as targeted AI deployment can help make prior authorization workflows more efficient.

Agentic AI is reshaping pharma market entry by enabling real-time, data-driven insights that allow companies to ask more complex strategic questions and act faster — with greater precision.

Jamie Singer and Matt Flora discuss how cybersecurity threats in pharma are evolving beyond ransomware to include data extortion, supply chain attacks, and AI-driven risks.

Data-driven decision-making, evolving access models, and accelerating adoption of AI create a complex commercialization landscape.

Inizio launches integrated hub services model to streamline patient access, reimbursement, and adherence, reflecting a broader industry shift toward data-driven, end-to-end patient support strategies.

Accurate and reliable data is essential to provide leaders with the right information to power these systems.

Organizations must build a strong foundation that anchors AI deployments in critical areas.

Recent breakthroughs in artificial intelligence allow specialized language models to automatically extract critical information from thousands of complex drug labels in minutes instead of days.

Companion diagnostics are reshaping precision oncology, but clinical adoption continues to lag behind scientific progress due to regulatory, operational and reimbursement barriers.

The agentic model is emerging as a strategic tool to compress analysis timelines, coordinate cross-functional teams and surface competitive intelligence in real time.

Reliable, domain-specific AI models grounded in validated clinical evidence are emerging as essential to safely scaling generative AI across healthcare applications.

In Part 2 of our podcast video episode with ZS CEO Pratap Khedkar, he breaks down pharma's need to move beyond AI pilots to scalable impact—and how companies can "go from informing to solving" while navigating trust, regulation, and a rapidly shifting patient dynamic.

Boring AI operates quietly in the background, embedded deep within hospital EPR workflows, capturing structured, multimodal clinical data in real time at the point of care.

By correlating behavior data with performance outcomes, it becomes possible to predict what actually drives results.

Faruk Capan provides insights into the future of proprietary AI platforms.